You are here

Glasdegib Renal Impairment Study

Last updated on October 9, 2018

FOR MORE INFORMATION
Study Location
University of Miami Division of Clinical Pharmacology
Miami, Florida, 33136 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Renal Impairment
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-75 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy female subjects of non child bearing potential and/or male subjects who, at
the time of screening, are between the ages of 18 and 75 years, inclusive. Healthy is
defined as no clinically relevant abnormalities identified by a detailed medical
history, full physical examination, including blood pressure and pulse rate
measurement, 12 lead ECG or clinical laboratory tests.

2. Female subjects of nonchildbearing potential must meet at least 1 of the following
criteria:

1. Achieved postmenopausal status, defined as follows: cessation of regular menses
for at least 12 consecutive months with no alternative pathological or
physiological cause; with a serum follicle stimulating hormone (FSH) level
confirming the postmenopausal state;

2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;

3. Have medically confirmed ovarian failure. All other female subjects (including
females with tubal ligations) are considered to be of childbearing potential.

3. Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).

4. Evidence of a personally signed and dated informed consent document indicating that
the subject (or a legal representative) has been informed of all pertinent aspects of
the study.

5. Subjects who are willing and able to comply with all scheduled visits, treatment plan,
laboratory tests, and other study procedures.

Subjects with Normal Renal Function will Need to Meet the Following Criteria in addition -

1. Normal renal function, eGFR=>90 mL/min, based on the MDRD equation.

2. Matched for age (+/-10years) weight +/-15kg, and gender to subjects in the impaired
renal function groups

Subjects with Impaired Renal Function will Need to Meet the Following Criteria in Addition
to Those Above

1. Good general health commensurate with the population with chronic kidney disease
(renal impairment). 'Health' is defined as no clinically relevant abnormalities (with
the exception of hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart
disease, etc. as long as, in the opinion of the investigator, the subject is medically
stable, is on a stable drug regimen and can abide by the meals and dietary
restrictions outlined in protocol identified by a detailed medical history, full
physical examination, measurement of pulse rate and 12 lead ECG as well as clinical
laboratory tests (except serum creatinine and eGFR).

2. Stable drug regimen defined as not starting a new drug or changing dosage within seven
days or five half lives (whichever is longer) before dosing the study drug.

3. Any form of renal impairment except acute nephritic syndrome (subjects with history of
previous nephritic syndrome but in remission can be included).

4. Meet one of the following eGFR criteria during the screening period based on the MDRD
equation:

1. Moderate renal impairment: eGFR 30 mL/min and

2. Severe renal impairment: eGFR subjects in all groups, the values of serum creatinine obtained at the two
screening visits should not be more than 20% different.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

-Any condition possibly affecting drug absorption (eg, gastrectomy,
achlorhydria).

Renal allograft recipients

Urinary incontinence without catheterization.

Concurrent use of any of the following food or drugs known to inhibit CYP3A4
(consult the Sponsor if in doubt whether a food or a drug falls into any of the
above categories) within 7 days or 5 half lives (whichever is longer) prior to
the dose of glasdegib, until the completion of the last PK sample collection.

Concurrent use of any of the following food or drugs known to induce CYP3A4
(consult the Sponsor if in doubt whether a food or a drug falls into any of the
above categories) within 12 days or 5 half lives (whichever is longer) prior to
the first dose of trial medication until the completion of the last PK sample
collection.

Pregnant female subjects; breastfeeding female subjects; fertile male subjects
who are unwilling or unable to use two highly effective methods of contraception
as outlined in this protocol for the duration of the study and for at least 90
days after the last dose of investigational product and, refrain from sperm
donation for the duration of the Study and for at least 90 days after the last
dose of investigational product.

Subjects with ANY of the following abnormalities in clinical laboratory tests at
Screening, as assessed by the study specific laboratory and confirmed by a single
repeat test, if deemed necessary:

- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level >
upper limit of normal (ULN);

- Total bilirubin level 1.5 × ULN; subjects with a history of Gilbert's
syndrome may have direct bilirubin measured and would be eligible for this
study provided the direct bilirubin level is not greater than 0.5 mg/dL.

For subjects with renal impairment, the following important additional criteria
are:

Subjects with other clinically significant disease that may affect the safety of
the subject or that may affect the pharmacokinetics of glasdegib (including drug
allergies, but excluding untreated, asymptomatic, seasonal allergies at time of
dosing). Subjects with any significant hepatic, cardiac, or pulmonary disease or
subjects who are clinically nephrotic. Hypertension, diabetes mellitus,
hyperparathyroidism, ischemic heart disease, etc is not cause for exclusion as
long as the subject is medically stable and any drugs that are administered for
these conditions are not expected to interfere with the pharmacokinetics of
glasdegib.

Screening blood pressure =>180mm Hg (systolic) or>=110 mm Hg (diastolic),
following at least 5 minutes of supine rest. If initial blood pressure (BP) is
180 mm Hg (systolic) or 110 mm Hg (diastolic), the BP should be repeated two more
times and the average of the three BP values should be used to determine the
subject's eligibility.

Screening supine 12 lead ECG demonstrating QTcF >470 msec or a QRS interval >120
msec. If initial QTcF exceeds 470 msec, or QRS exceeds 120 msec, the ECG should
be repeated two more times and the average of the three QTcF or QRS values should
be used to determine the subject's eligibility.

NCT03596567
Pfizer
Completed
Glasdegib Renal Impairment Study

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Renal Cell Cancer
NCT02684006
All Genders
18+
Years
Multiple Sites
Hepatic Impairment
NCT03626415
All Genders
18+
Years
Multiple Sites
Hepatic Impairment
NCT03660241
All Genders
18+
Years
Orlando, Florida
Glasdegib Renal Impairment Study
A Phase 1, Open-label, Single Dose, Parallel Group Study To Evaluate The Pharmacokinetics Of Glasdegib (Pf-04449913) In Subjects With Impaired Renal Function
The goal of this study is to administer single dose (100 mg) glasdegib tablet to subjects with normal, moderate and severe renal impairment and estimate the effect, if any, of this renal impairment on glasdegib pharmacokinetics.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Renal Impairment
  • Drug: Glasdegib single 100 mg dose in normal healthy subjects
    A single dose of 100 mg glasdegib tablet will be administered after an overnight fast, followed by serial PK collection, discharge and follow -up.
  • Drug: Glasdegib single 100 mg dose in moderate renal impairment subjects
    A single dose of 100 mg glasdegib tablet will be administered to subjects with moderate renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
  • Drug: Glasdegib single 100 mg dose in severe renal impairment subjects
    A single dose of 100 mg glasdegib tablet will be administered to subjects with severe renal impairment, after an overnight fast, followed by serial PK collection, discharge and follow -up.
  • Experimental: Normal Renal Function Group
    Subjects with estimated glomerular filtration rate (eGFR) of => 90 ml/min
    Intervention: Drug: Glasdegib single 100 mg dose in normal healthy subjects
  • Experimental: Moderate Renal Impairment Group
    Subjects with estimated glomerular filtration rate (eGFR) of => 30ml/min and < 60 ml/min
    Intervention: Drug: Glasdegib single 100 mg dose in moderate renal impairment subjects
  • Experimental: Severe Renal Impairment Group
    Subjects with estimated glomerular filtration rate (eGFR) of < 30 ml/min and not requiring dialysis
    Intervention: Drug: Glasdegib single 100 mg dose in severe renal impairment subjects
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
18
Same as current
August 2, 2019
August 2, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy female subjects of non child bearing potential and/or male subjects who, at the time of screening, are between the ages of 18 and 75 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.
  2. Female subjects of nonchildbearing potential must meet at least 1 of the following criteria:

    1. Achieved postmenopausal status, defined as follows: cessation of regular menses for at least 12 consecutive months with no alternative pathological or physiological cause; with a serum follicle stimulating hormone (FSH) level confirming the postmenopausal state;
    2. Have undergone a documented hysterectomy and/or bilateral oophorectomy;
    3. Have medically confirmed ovarian failure. All other female subjects (including females with tubal ligations) are considered to be of childbearing potential.
  3. Body mass index (BMI) of 17.5 to 40 kg/m2; and a total body weight >50 kg (110 lb).
  4. Evidence of a personally signed and dated informed consent document indicating that the subject (or a legal representative) has been informed of all pertinent aspects of the study.
  5. Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Subjects with Normal Renal Function will Need to Meet the Following Criteria in addition -

  1. Normal renal function, eGFR=>90 mL/min, based on the MDRD equation.
  2. Matched for age (+/-10years) weight +/-15kg, and gender to subjects in the impaired renal function groups

Subjects with Impaired Renal Function will Need to Meet the Following Criteria in Addition to Those Above

  1. Good general health commensurate with the population with chronic kidney disease (renal impairment). 'Health' is defined as no clinically relevant abnormalities (with the exception of hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc. as long as, in the opinion of the investigator, the subject is medically stable, is on a stable drug regimen and can abide by the meals and dietary restrictions outlined in protocol identified by a detailed medical history, full physical examination, measurement of pulse rate and 12 lead ECG as well as clinical laboratory tests (except serum creatinine and eGFR).
  2. Stable drug regimen defined as not starting a new drug or changing dosage within seven days or five half lives (whichever is longer) before dosing the study drug.
  3. Any form of renal impairment except acute nephritic syndrome (subjects with history of previous nephritic syndrome but in remission can be included).
  4. Meet one of the following eGFR criteria during the screening period based on the MDRD equation:

    1. Moderate renal impairment: eGFR 30 mL/min and <60 mL/min, or
    2. Severe renal impairment: eGFR <30 mL/min, but not requiring hemodialysis. For subjects in all groups, the values of serum creatinine obtained at the two screening visits should not be more than 20% different.

      Exclusion Criteria:

      -Any condition possibly affecting drug absorption (eg, gastrectomy, achlorhydria).

      Renal allograft recipients

      Urinary incontinence without catheterization.

      Concurrent use of any of the following food or drugs known to inhibit CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 7 days or 5 half lives (whichever is longer) prior to the dose of glasdegib, until the completion of the last PK sample collection.

      Concurrent use of any of the following food or drugs known to induce CYP3A4 (consult the Sponsor if in doubt whether a food or a drug falls into any of the above categories) within 12 days or 5 half lives (whichever is longer) prior to the first dose of trial medication until the completion of the last PK sample collection.

      Pregnant female subjects; breastfeeding female subjects; fertile male subjects who are unwilling or unable to use two highly effective methods of contraception as outlined in this protocol for the duration of the study and for at least 90 days after the last dose of investigational product and, refrain from sperm donation for the duration of the Study and for at least 90 days after the last dose of investigational product.

      Subjects with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

      • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level > upper limit of normal (ULN);
      • Total bilirubin level 1.5 × ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is not greater than 0.5 mg/dL.

      For subjects with renal impairment, the following important additional criteria are:

      Subjects with other clinically significant disease that may affect the safety of the subject or that may affect the pharmacokinetics of glasdegib (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). Subjects with any significant hepatic, cardiac, or pulmonary disease or subjects who are clinically nephrotic. Hypertension, diabetes mellitus, hyperparathyroidism, ischemic heart disease, etc is not cause for exclusion as long as the subject is medically stable and any drugs that are administered for these conditions are not expected to interfere with the pharmacokinetics of glasdegib.

      Screening blood pressure =>180mm Hg (systolic) or>=110 mm Hg (diastolic), following at least 5 minutes of supine rest. If initial blood pressure (BP) is 180 mm Hg (systolic) or 110 mm Hg (diastolic), the BP should be repeated two more times and the average of the three BP values should be used to determine the subject's eligibility.

      Screening supine 12 lead ECG demonstrating QTcF >470 msec or a QRS interval >120 msec. If initial QTcF exceeds 470 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the average of the three QTcF or QRS values should be used to determine the subject's eligibility.

Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
Yes

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
United States
 
 
NCT03596567
B1371017
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: No
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2018

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now